Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Diabetes Home
    • Products
      Diabetes Treatments
    • Professional Resources
      Product Resources Library Insulin & Type 1 Diabetes
    • Professional Training
      Insulin Pen Training
  • Sample Requests
    • Diabetes Education
      Clinical Education Library Diabetes Risk Assessment Tool Diabetes & Cardiovascular Disease
    • Treatment Guidelines
      ADA Standards of Care AACE Diabetes Guidelines
    • Additional Resources
      Utilizing Your EHR Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Insurance Coverage Affordability Resources
    • Support Program
      Diabetes Management Cardiovascular Risk Management
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Zegalogue® (dasiglucagon) injection 0.6mg/0.6mL logo
Important Safety Information | Patient Site
Prescribing Information
    • Identifying the risk
    • The importance of rescue treatment
    • Adult Study Results
    • Pediatric study results
    • Adverse reactions
    • The devices
    • Glucagon analog
Zegalogue® (dasiglucagon) injection 0.6mg/0.6mL logo

Prescribing Information
Important Safety Information | Patient Site

The first and only glucagon analog for the treatment of severe hypoglycemia1

ZEGALOGUE® (dasiglucagon) injection offers product stability in an aqueous solution1

It was developed with strategic structural modifications by substituting 7 of the 29 amino acids found in native glucagon.1,2

Dasiglucagon is a glucagon receptor agonist that increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for ZEGALOGUE to produce an antihypoglycemic effect.1

dasiglucagon
yellow circle

Modified amino acid

red circle

Native glucagon amino acid

Indication and Usage for ZEGALOGUE® (dasiglucagon) injection 0.6 mg/0.6 mL

ZEGALOGUE® (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

Important Safety Information

Contraindications

ZEGALOGUE® is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.

Warnings and Precautions

  • ZEGALOGUE® is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
  • In patients with insulinoma, administration of glucagon products may produce an initial increase in blood glucose; however, ZEGALOGUE® administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. ZEGALOGUE® is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE®, give glucose orally or intravenously.
  • Allergic reactions have been reported with glucagon products; these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.
  • ZEGALOGUE® is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for ZEGALOGUE® administration to be effective. Patients with these conditions should be treated with glucose.

Adverse Reactions 

  • The most common adverse reactions (≥2%) associated with ZEGALOGUE® in adults were nausea, vomiting, headache, diarrhea and injection site pain; in pediatrics: nausea, vomiting, headache and injection site pain.

Drug Interactions

  • Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE®. In patients taking indomethacin, ZEGALOGUE® may lose its ability to raise blood glucose or may produce hypoglycemia. ZEGALOGUE® may increase the anticoagulant effect of warfarin.

Please see Zegalogue® Full Prescribing Information.

References: 1. Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; April 2021. 2. Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531-537. doi:10.2337/dc17-1402 3. Macchi F, Wenander C, Lundholt BK. Dasiglucagon is a novel stable glucagon analog with fast glucose response following subcutaneous injection in hypoglycemic rats. Poster presented at: Virtual European Association for the Study of Diabetes Annual Meeting 2020; September 21-25, 2020.

Diabetes
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Diabetes Home
  • Product Information
    Products
    • Diabetes Treatments
    Professional Resources
    • Product Resources Library
      Insulin & Type 1 Diabetes
    Professional Training
    • Insulin Pen Training
  • Sample Requests
  • Professional Education
    Diabetes Education
    • Clinical Education Library
      Diabetes Risk Assessment Tool
      Diabetes & Cardiovascular Disease
    Treatment Guidelines
    • ADA Standards of Care
      AACE Diabetes Guidelines
    Additional Resources
    • Utilizing Your EHR
      Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Insurance Coverage
      Affordability Resources
    Support Program
    • Diabetes Management
      Cardiovascular Risk Management

Zegalogue®, Cornerstones4Care®, NovoCare®, NovoFine Plus®, NovoFine®, and NovoTwist® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

All other trademarks, registered or unregistered, are the property of their respective owners.

Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22ZGL00009 December 2022

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program